ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Human Rabies Immunoglobulin (IM) Market Research Report 2026
Published Date: 2026-01-16
|
Report Code: QYRE-Auto-39X8702
Home | Market Reports
Global Human Rabies Immunoglobulin IM Market Outlook 2022
BUY CHAPTERS

Global Human Rabies Immunoglobulin (IM) Market Research Report 2026

Code: QYRE-Auto-39X8702
Report
2026-01-16
Pages:118
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Sichuan Yuanda Shuyang
Kamada
CBPO
Shuanglin Bio
Weiguang Bio
Shanghai Raas
Bharat Serum
VINS
Grifols S A
CSL Behring
Sanofi
Tiantan Bio

Human Rabies Immunoglobulin (IM) Market Size

The global Human Rabies Immunoglobulin (IM) market was valued at US$ 337 million in 2025 and is anticipated to reach US$ 419 million by 2032, at a CAGR of 3.2% from 2026 to 2032.

Human Rabies Immunoglobulin (IM) Market

Human Rabies Immunoglobulin (IM) Market

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Human Rabies Immunoglobulin (IM) competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
Rabies immunoglobulin (RIG) is a medication made up of antibodies against the rabies virus. It is used to prevent rabies following exposure. Human Rabies Immunoglobulin (IM) is rabies immunoglobulin antibody by the high price of healthy human plasma protein low temperature ethanol separation or other separation methods approved separation and purification, and by virus removal and inactivation treatment is made. Mainly used for rabies or other crazy animal bites, scratches patient's passive immunization. In this report, we study ERIG (Equine Rabies Immunoglobulin) and HRIG (Human Rabies Immunoglobulin)
The rising incidence of rabies, especially in developing countries, is a key driver of the human rabies immunoglobulin market. Rabies remains a significant public health concern, particularly in regions where animal vaccination programs are insufficient. Post-exposure prophylaxis (PEP), which includes human rabies immunoglobulin, is critical for preventing the virus after a bite from a rabid animal. Increasing awareness of rabies prevention, government initiatives, and partnerships with international health organizations have boosted demand for human rabies immunoglobulin in both rural and urban areas.
A major challenge in the human rabies immunoglobulin market is its limited availability and high cost, particularly in low- and middle-income countries where rabies is most prevalent. The production of immunoglobulins requires advanced technology and biological materials, making it costly and sometimes scarce in regions with insufficient healthcare infrastructure. Additionally, the need for timely administration after exposure poses logistical difficulties, especially in remote areas, where access to healthcare facilities may be delayed, potentially limiting the effectiveness of the treatment.
Asia-Pacific is expected to experience the highest growth in the market during the forecast period.
This report delivers a comprehensive overview of the global Human Rabies Immunoglobulin (IM) market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Human Rabies Immunoglobulin (IM). The Human Rabies Immunoglobulin (IM) market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Human Rabies Immunoglobulin (IM) market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Human Rabies Immunoglobulin (IM) manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation

Scope of Human Rabies Immunoglobulin (IM) Market Report

Report Metric Details
Report Name Human Rabies Immunoglobulin (IM) Market
Accounted market size in 2025 US$ 337 million
Forecasted market size in 2032 US$ 419 million
CAGR 3.2%
Base Year 2025
Forecasted years 2026 - 2032
Segment by Type
  • ERIG
  • HRIG
by Application
  • Category II Exposure
  • Category III Exposure
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company CSL Behring, Grifols, Sanofi, Sichuan Yuanda Shuyang, Tiantan Bio, Kamada, CBPO, Shuanglin Bio, Weiguang Bio, Shanghai RAAS, Bharat Serum, VINS
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
  • Chapter 2: Provides a detailed analysis of the competitive landscape for Human Rabies Immunoglobulin (IM) manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
  • Chapter 3: Examines Human Rabies Immunoglobulin (IM) sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
  • Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
  • Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
  • Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
  • Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
  • Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
  • Chapter 9: Summarizes the key findings and conclusions of the report.

FAQ for this report

How fast is Human Rabies Immunoglobulin (IM) Market growing?

Ans: The Human Rabies Immunoglobulin (IM) Market witnessing a CAGR of 3.2% during the forecast period 2026-2032.

What is the Human Rabies Immunoglobulin (IM) Market size in 2032?

Ans: The Human Rabies Immunoglobulin (IM) Market size in 2032 will be US$ 419 million.

Who are the main players in the Human Rabies Immunoglobulin (IM) Market report?

Ans: The main players in the Human Rabies Immunoglobulin (IM) Market are CSL Behring, Grifols, Sanofi, Sichuan Yuanda Shuyang, Tiantan Bio, Kamada, CBPO, Shuanglin Bio, Weiguang Bio, Shanghai RAAS, Bharat Serum, VINS

What are the Application segmentation covered in the Human Rabies Immunoglobulin (IM) Market report?

Ans: The Applications covered in the Human Rabies Immunoglobulin (IM) Market report are Category II Exposure, Category III Exposure

What are the Type segmentation covered in the Human Rabies Immunoglobulin (IM) Market report?

Ans: The Types covered in the Human Rabies Immunoglobulin (IM) Market report are ERIG, HRIG

1 Human Rabies Immunoglobulin (IM) Market Overview
1.1 Product Definition
1.2 Human Rabies Immunoglobulin (IM) by Type
1.2.1 Global Human Rabies Immunoglobulin (IM) Market Value by Type: 2025 vs 2032
1.2.2 ERIG
1.2.3 HRIG
1.3 Human Rabies Immunoglobulin (IM) by Application
1.3.1 Global Human Rabies Immunoglobulin (IM) Market Value by Application: 2025 vs 2032
1.3.2 Category II Exposure
1.3.3 Category III Exposure
1.4 Global Human Rabies Immunoglobulin (IM) Market Size Estimates and Forecasts
1.4.1 Global Human Rabies Immunoglobulin (IM) Revenue 2021–2032
1.4.2 Global Human Rabies Immunoglobulin (IM) Sales 2021–2032
1.4.3 Global Human Rabies Immunoglobulin (IM) Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Human Rabies Immunoglobulin (IM) Market Competition by Manufacturers
2.1 Global Human Rabies Immunoglobulin (IM) Sales Market Share by Manufacturers (2021–2026)
2.2 Global Human Rabies Immunoglobulin (IM) Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Human Rabies Immunoglobulin (IM) Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Human Rabies Immunoglobulin (IM), Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Human Rabies Immunoglobulin (IM), Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Human Rabies Immunoglobulin (IM), Product Types and Applications
2.7 Global Key Manufacturers of Human Rabies Immunoglobulin (IM), Date of Entry into the Industry
2.8 Global Human Rabies Immunoglobulin (IM) Market Competitive Situation and Trends
2.8.1 Global Human Rabies Immunoglobulin (IM) Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Human Rabies Immunoglobulin (IM) Players Market Share by Revenue
2.8.3 Global Human Rabies Immunoglobulin (IM) Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Human Rabies Immunoglobulin (IM) Market Scenario by Region
3.1 Global Human Rabies Immunoglobulin (IM) Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Human Rabies Immunoglobulin (IM) Sales by Region: 2021–2032
3.2.1 Global Human Rabies Immunoglobulin (IM) Sales by Region: 2021–2026
3.2.2 Global Human Rabies Immunoglobulin (IM) Sales by Region: 2027–2032
3.3 Global Human Rabies Immunoglobulin (IM) Revenue by Region: 2021–2032
3.3.1 Global Human Rabies Immunoglobulin (IM) Revenue by Region: 2021–2026
3.3.2 Global Human Rabies Immunoglobulin (IM) Revenue by Region: 2027–2032
3.4 North America Human Rabies Immunoglobulin (IM) Market Facts & Figures by Country
3.4.1 North America Human Rabies Immunoglobulin (IM) Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Human Rabies Immunoglobulin (IM) Sales by Country (2021–2032)
3.4.3 North America Human Rabies Immunoglobulin (IM) Revenue by Country (2021–2032)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Human Rabies Immunoglobulin (IM) Market Facts & Figures by Country
3.5.1 Europe Human Rabies Immunoglobulin (IM) Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Human Rabies Immunoglobulin (IM) Sales by Country (2021–2032)
3.5.3 Europe Human Rabies Immunoglobulin (IM) Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Human Rabies Immunoglobulin (IM) Market Facts & Figures by Region
3.6.1 Asia Pacific Human Rabies Immunoglobulin (IM) Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Human Rabies Immunoglobulin (IM) Sales by Region (2021–2032)
3.6.3 Asia Pacific Human Rabies Immunoglobulin (IM) Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Human Rabies Immunoglobulin (IM) Market Facts & Figures by Country
3.7.1 Latin America Human Rabies Immunoglobulin (IM) Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Human Rabies Immunoglobulin (IM) Sales by Country (2021–2032)
3.7.3 Latin America Human Rabies Immunoglobulin (IM) Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Human Rabies Immunoglobulin (IM) Market Facts & Figures by Country
3.8.1 Middle East and Africa Human Rabies Immunoglobulin (IM) Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Human Rabies Immunoglobulin (IM) Sales by Country (2021–2032)
3.8.3 Middle East and Africa Human Rabies Immunoglobulin (IM) Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Human Rabies Immunoglobulin (IM) Sales by Type (2021–2032)
4.1.1 Global Human Rabies Immunoglobulin (IM) Sales by Type (2021–2026)
4.1.2 Global Human Rabies Immunoglobulin (IM) Sales by Type (2027–2032)
4.1.3 Global Human Rabies Immunoglobulin (IM) Sales Market Share by Type (2021–2032)
4.2 Global Human Rabies Immunoglobulin (IM) Revenue by Type (2021–2032)
4.2.1 Global Human Rabies Immunoglobulin (IM) Revenue by Type (2021–2026)
4.2.2 Global Human Rabies Immunoglobulin (IM) Revenue by Type (2027–2032)
4.2.3 Global Human Rabies Immunoglobulin (IM) Revenue Market Share by Type (2021–2032)
4.3 Global Human Rabies Immunoglobulin (IM) Price by Type (2021–2032)
5 Segment by Application
5.1 Global Human Rabies Immunoglobulin (IM) Sales by Application (2021–2032)
5.1.1 Global Human Rabies Immunoglobulin (IM) Sales by Application (2021–2026)
5.1.2 Global Human Rabies Immunoglobulin (IM) Sales by Application (2027–2032)
5.1.3 Global Human Rabies Immunoglobulin (IM) Sales Market Share by Application (2021–2032)
5.2 Global Human Rabies Immunoglobulin (IM) Revenue by Application (2021–2032)
5.2.1 Global Human Rabies Immunoglobulin (IM) Revenue by Application (2021–2026)
5.2.2 Global Human Rabies Immunoglobulin (IM) Revenue by Application (2027–2032)
5.2.3 Global Human Rabies Immunoglobulin (IM) Revenue Market Share by Application (2021–2032)
5.3 Global Human Rabies Immunoglobulin (IM) Price by Application (2021–2032)
6 Key Companies Profiled
6.1 CSL Behring
6.1.1 CSL Behring Company Information
6.1.2 CSL Behring Description and Business Overview
6.1.3 CSL Behring Human Rabies Immunoglobulin (IM) Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 CSL Behring Human Rabies Immunoglobulin (IM) Product Portfolio
6.1.5 CSL Behring Recent Developments/Updates
6.2 Grifols
6.2.1 Grifols Company Information
6.2.2 Grifols Description and Business Overview
6.2.3 Grifols Human Rabies Immunoglobulin (IM) Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Grifols Human Rabies Immunoglobulin (IM) Product Portfolio
6.2.5 Grifols Recent Developments/Updates
6.3 Sanofi
6.3.1 Sanofi Company Information
6.3.2 Sanofi Description and Business Overview
6.3.3 Sanofi Human Rabies Immunoglobulin (IM) Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Sanofi Human Rabies Immunoglobulin (IM) Product Portfolio
6.3.5 Sanofi Recent Developments/Updates
6.4 Sichuan Yuanda Shuyang
6.4.1 Sichuan Yuanda Shuyang Company Information
6.4.2 Sichuan Yuanda Shuyang Description and Business Overview
6.4.3 Sichuan Yuanda Shuyang Human Rabies Immunoglobulin (IM) Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Sichuan Yuanda Shuyang Human Rabies Immunoglobulin (IM) Product Portfolio
6.4.5 Sichuan Yuanda Shuyang Recent Developments/Updates
6.5 Tiantan Bio
6.5.1 Tiantan Bio Company Information
6.5.2 Tiantan Bio Description and Business Overview
6.5.3 Tiantan Bio Human Rabies Immunoglobulin (IM) Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Tiantan Bio Human Rabies Immunoglobulin (IM) Product Portfolio
6.5.5 Tiantan Bio Recent Developments/Updates
6.6 Kamada
6.6.1 Kamada Company Information
6.6.2 Kamada Description and Business Overview
6.6.3 Kamada Human Rabies Immunoglobulin (IM) Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Kamada Human Rabies Immunoglobulin (IM) Product Portfolio
6.6.5 Kamada Recent Developments/Updates
6.7 CBPO
6.7.1 CBPO Company Information
6.7.2 CBPO Description and Business Overview
6.7.3 CBPO Human Rabies Immunoglobulin (IM) Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 CBPO Human Rabies Immunoglobulin (IM) Product Portfolio
6.7.5 CBPO Recent Developments/Updates
6.8 Shuanglin Bio
6.8.1 Shuanglin Bio Company Information
6.8.2 Shuanglin Bio Description and Business Overview
6.8.3 Shuanglin Bio Human Rabies Immunoglobulin (IM) Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Shuanglin Bio Human Rabies Immunoglobulin (IM) Product Portfolio
6.8.5 Shuanglin Bio Recent Developments/Updates
6.9 Weiguang Bio
6.9.1 Weiguang Bio Company Information
6.9.2 Weiguang Bio Description and Business Overview
6.9.3 Weiguang Bio Human Rabies Immunoglobulin (IM) Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Weiguang Bio Human Rabies Immunoglobulin (IM) Product Portfolio
6.9.5 Weiguang Bio Recent Developments/Updates
6.10 Shanghai RAAS
6.10.1 Shanghai RAAS Company Information
6.10.2 Shanghai RAAS Description and Business Overview
6.10.3 Shanghai RAAS Human Rabies Immunoglobulin (IM) Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 Shanghai RAAS Human Rabies Immunoglobulin (IM) Product Portfolio
6.10.5 Shanghai RAAS Recent Developments/Updates
6.11 Bharat Serum
6.11.1 Bharat Serum Company Information
6.11.2 Bharat Serum Description and Business Overview
6.11.3 Bharat Serum Human Rabies Immunoglobulin (IM) Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 Bharat Serum Human Rabies Immunoglobulin (IM) Product Portfolio
6.11.5 Bharat Serum Recent Developments/Updates
6.12 VINS
6.12.1 VINS Company Information
6.12.2 VINS Description and Business Overview
6.12.3 VINS Human Rabies Immunoglobulin (IM) Sales, Revenue, and Gross Margin (2021–2026)
6.12.4 VINS Human Rabies Immunoglobulin (IM) Product Portfolio
6.12.5 VINS Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Human Rabies Immunoglobulin (IM) Industry Chain Analysis
7.2 Human Rabies Immunoglobulin (IM) Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Human Rabies Immunoglobulin (IM) Production Mode & Process Analysis
7.4 Human Rabies Immunoglobulin (IM) Sales and Marketing
7.4.1 Human Rabies Immunoglobulin (IM) Sales Channels
7.4.2 Human Rabies Immunoglobulin (IM) Distributors
7.5 Human Rabies Immunoglobulin (IM) Customer Analysis
8 Human Rabies Immunoglobulin (IM) Market Dynamics
8.1 Human Rabies Immunoglobulin (IM) Industry Trends
8.2 Human Rabies Immunoglobulin (IM) Market Drivers
8.3 Human Rabies Immunoglobulin (IM) Market Challenges
8.4 Human Rabies Immunoglobulin (IM) Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Sichuan Yuanda Shuyang
Kamada
CBPO
Shuanglin Bio
Weiguang Bio
Shanghai Raas
Bharat Serum
VINS
Grifols S A
CSL Behring
Sanofi
Tiantan Bio
List of Tables
 Table 1. Global Human Rabies Immunoglobulin (IM) Market Value by Type (US$ Million), 2025 vs 2032
 Table 2. Global Human Rabies Immunoglobulin (IM) Market Value by Application (US$ Million), 2025 vs 2032
 Table 3. Global Human Rabies Immunoglobulin (IM) Market Competitive Situation by Manufacturers in 2025
 Table 4. Global Human Rabies Immunoglobulin (IM) Sales (K Units) of Key Manufacturers (2021–2026)
 Table 5. Global Human Rabies Immunoglobulin (IM) Sales Market Share by Manufacturers (2021–2026)
 Table 6. Global Human Rabies Immunoglobulin (IM) Revenue (US$ Million) by Manufacturers (2021–2026)
 Table 7. Global Human Rabies Immunoglobulin (IM) Revenue Share by Manufacturers (2021–2026)
 Table 8. Global Market Human Rabies Immunoglobulin (IM) Average Price (US$/Unit) of Key Manufacturers (2021–2026)
 Table 9. Global Key Players of Human Rabies Immunoglobulin (IM), Industry Ranking, 2023 vs 2024 vs 2025
 Table 10. Global Key Manufacturers of Human Rabies Immunoglobulin (IM), Manufacturing Sites and Headquarters
 Table 11. Global Key Manufacturers of Human Rabies Immunoglobulin (IM), Product Types and Applications
 Table 12. Global Key Manufacturers of Human Rabies Immunoglobulin (IM), Date of Entry into the Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Human Rabies Immunoglobulin (IM) Companies by Tier (Tier 1, Tier 2, Tier 3), based on Human Rabies Immunoglobulin (IM) Revenue, 2025
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Human Rabies Immunoglobulin (IM) Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 17. Global Human Rabies Immunoglobulin (IM) Sales by Region (K Units), 2021–2026
 Table 18. Global Human Rabies Immunoglobulin (IM) Sales Market Share by Region (2021–2026)
 Table 19. Global Human Rabies Immunoglobulin (IM) Sales by Region (K Units), 2027–2032
 Table 20. Global Human Rabies Immunoglobulin (IM) Sales Market Share by Region (2027–2032)
 Table 21. Global Human Rabies Immunoglobulin (IM) Revenue by Region (US$ Million), 2021–2026
 Table 22. Global Human Rabies Immunoglobulin (IM) Revenue Market Share by Region (2021–2026)
 Table 23. Global Human Rabies Immunoglobulin (IM) Revenue by Region (US$ Million), 2027–2032
 Table 24. Global Human Rabies Immunoglobulin (IM) Revenue Market Share by Region (2027–2032)
 Table 25. North America Human Rabies Immunoglobulin (IM) Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 26. North America Human Rabies Immunoglobulin (IM) Sales by Country (K Units), 2021–2026
 Table 27. North America Human Rabies Immunoglobulin (IM) Sales by Country (K Units), 2027–2032
 Table 28. North America Human Rabies Immunoglobulin (IM) Revenue by Country (US$ Million), 2021–2026
 Table 29. North America Human Rabies Immunoglobulin (IM) Revenue by Country (US$ Million), 2027–2032
 Table 30. Europe Human Rabies Immunoglobulin (IM) Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 31. Europe Human Rabies Immunoglobulin (IM) Sales by Country (K Units), 2021–2026
 Table 32. Europe Human Rabies Immunoglobulin (IM) Sales by Country (K Units), 2027–2032
 Table 33. Europe Human Rabies Immunoglobulin (IM) Revenue by Country (US$ Million), 2021–2026
 Table 34. Europe Human Rabies Immunoglobulin (IM) Revenue by Country (US$ Million), 2027–2032
 Table 35. Asia Pacific Human Rabies Immunoglobulin (IM) Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
 Table 36. Asia Pacific Human Rabies Immunoglobulin (IM) Sales by Region (K Units), 2021–2026
 Table 37. Asia Pacific Human Rabies Immunoglobulin (IM) Sales by Region (K Units), 2027–2032
 Table 38. Asia Pacific Human Rabies Immunoglobulin (IM) Revenue by Region (US$ Million), 2021–2026
 Table 39. Asia Pacific Human Rabies Immunoglobulin (IM) Revenue by Region (US$ Million), 2027–2032
 Table 40. Latin America Human Rabies Immunoglobulin (IM) Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 41. Latin America Human Rabies Immunoglobulin (IM) Sales by Country (K Units), 2021–2026
 Table 42. Latin America Human Rabies Immunoglobulin (IM) Sales by Country (K Units), 2027–2032
 Table 43. Latin America Human Rabies Immunoglobulin (IM) Revenue by Country (US$ Million), 2021–2026
 Table 44. Latin America Human Rabies Immunoglobulin (IM) Revenue by Country (US$ Million), 2027–2032
 Table 45. Middle East and Africa Human Rabies Immunoglobulin (IM) Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 46. Middle East and Africa Human Rabies Immunoglobulin (IM) Sales by Country (K Units), 2021–2026
 Table 47. Middle East and Africa Human Rabies Immunoglobulin (IM) Sales by Country (K Units), 2027–2032
 Table 48. Middle East and Africa Human Rabies Immunoglobulin (IM) Revenue by Country (US$ Million), 2021–2026
 Table 49. Middle East and Africa Human Rabies Immunoglobulin (IM) Revenue by Country (US$ Million), 2027–2032
 Table 50. Global Human Rabies Immunoglobulin (IM) Sales (K Units) by Type (2021–2026)
 Table 51. Global Human Rabies Immunoglobulin (IM) Sales (K Units) by Type (2027–2032)
 Table 52. Global Human Rabies Immunoglobulin (IM) Sales Market Share by Type (2021–2026)
 Table 53. Global Human Rabies Immunoglobulin (IM) Sales Market Share by Type (2027–2032)
 Table 54. Global Human Rabies Immunoglobulin (IM) Revenue (US$ Million) by Type (2021–2026)
 Table 55. Global Human Rabies Immunoglobulin (IM) Revenue (US$ Million) by Type (2027–2032)
 Table 56. Global Human Rabies Immunoglobulin (IM) Revenue Market Share by Type (2021–2026)
 Table 57. Global Human Rabies Immunoglobulin (IM) Revenue Market Share by Type (2027–2032)
 Table 58. Global Human Rabies Immunoglobulin (IM) Price (US$/Unit) by Type (2021–2026)
 Table 59. Global Human Rabies Immunoglobulin (IM) Price (US$/Unit) by Type (2027–2032)
 Table 60. Global Human Rabies Immunoglobulin (IM) Sales (K Units) by Application (2021–2026)
 Table 61. Global Human Rabies Immunoglobulin (IM) Sales (K Units) by Application (2027–2032)
 Table 62. Global Human Rabies Immunoglobulin (IM) Sales Market Share by Application (2021–2026)
 Table 63. Global Human Rabies Immunoglobulin (IM) Sales Market Share by Application (2027–2032)
 Table 64. Global Human Rabies Immunoglobulin (IM) Revenue (US$ Million) by Application (2021–2026)
 Table 65. Global Human Rabies Immunoglobulin (IM) Revenue (US$ Million) by Application (2027–2032)
 Table 66. Global Human Rabies Immunoglobulin (IM) Revenue Market Share by Application (2021–2026)
 Table 67. Global Human Rabies Immunoglobulin (IM) Revenue Market Share by Application (2027–2032)
 Table 68. Global Human Rabies Immunoglobulin (IM) Price (US$/Unit) by Application (2021–2026)
 Table 69. Global Human Rabies Immunoglobulin (IM) Price (US$/Unit) by Application (2027–2032)
 Table 70. CSL Behring Company Information
 Table 71. CSL Behring Description and Business Overview
 Table 72. CSL Behring Human Rabies Immunoglobulin (IM) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 73. CSL Behring Human Rabies Immunoglobulin (IM) Product
 Table 74. CSL Behring Recent Developments/Updates
 Table 75. Grifols Company Information
 Table 76. Grifols Description and Business Overview
 Table 77. Grifols Human Rabies Immunoglobulin (IM) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 78. Grifols Human Rabies Immunoglobulin (IM) Product
 Table 79. Grifols Recent Developments/Updates
 Table 80. Sanofi Company Information
 Table 81. Sanofi Description and Business Overview
 Table 82. Sanofi Human Rabies Immunoglobulin (IM) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 83. Sanofi Human Rabies Immunoglobulin (IM) Product
 Table 84. Sanofi Recent Developments/Updates
 Table 85. Sichuan Yuanda Shuyang Company Information
 Table 86. Sichuan Yuanda Shuyang Description and Business Overview
 Table 87. Sichuan Yuanda Shuyang Human Rabies Immunoglobulin (IM) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 88. Sichuan Yuanda Shuyang Human Rabies Immunoglobulin (IM) Product
 Table 89. Sichuan Yuanda Shuyang Recent Developments/Updates
 Table 90. Tiantan Bio Company Information
 Table 91. Tiantan Bio Description and Business Overview
 Table 92. Tiantan Bio Human Rabies Immunoglobulin (IM) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 93. Tiantan Bio Human Rabies Immunoglobulin (IM) Product
 Table 94. Tiantan Bio Recent Developments/Updates
 Table 95. Kamada Company Information
 Table 96. Kamada Description and Business Overview
 Table 97. Kamada Human Rabies Immunoglobulin (IM) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 98. Kamada Human Rabies Immunoglobulin (IM) Product
 Table 99. Kamada Recent Developments/Updates
 Table 100. CBPO Company Information
 Table 101. CBPO Description and Business Overview
 Table 102. CBPO Human Rabies Immunoglobulin (IM) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 103. CBPO Human Rabies Immunoglobulin (IM) Product
 Table 104. CBPO Recent Developments/Updates
 Table 105. Shuanglin Bio Company Information
 Table 106. Shuanglin Bio Description and Business Overview
 Table 107. Shuanglin Bio Human Rabies Immunoglobulin (IM) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 108. Shuanglin Bio Human Rabies Immunoglobulin (IM) Product
 Table 109. Shuanglin Bio Recent Developments/Updates
 Table 110. Weiguang Bio Company Information
 Table 111. Weiguang Bio Description and Business Overview
 Table 112. Weiguang Bio Human Rabies Immunoglobulin (IM) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 113. Weiguang Bio Human Rabies Immunoglobulin (IM) Product
 Table 114. Weiguang Bio Recent Developments/Updates
 Table 115. Shanghai RAAS Company Information
 Table 116. Shanghai RAAS Description and Business Overview
 Table 117. Shanghai RAAS Human Rabies Immunoglobulin (IM) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 118. Shanghai RAAS Human Rabies Immunoglobulin (IM) Product
 Table 119. Shanghai RAAS Recent Developments/Updates
 Table 120. Bharat Serum Company Information
 Table 121. Bharat Serum Description and Business Overview
 Table 122. Bharat Serum Human Rabies Immunoglobulin (IM) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 123. Bharat Serum Human Rabies Immunoglobulin (IM) Product
 Table 124. Bharat Serum Recent Developments/Updates
 Table 125. VINS Company Information
 Table 126. VINS Description and Business Overview
 Table 127. VINS Human Rabies Immunoglobulin (IM) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 128. VINS Human Rabies Immunoglobulin (IM) Product
 Table 129. VINS Recent Developments/Updates
 Table 130. Key Raw Materials Lists
 Table 131. Raw Materials Key Suppliers Lists
 Table 132. Human Rabies Immunoglobulin (IM) Distributors List
 Table 133. Human Rabies Immunoglobulin (IM) Customers List
 Table 134. Human Rabies Immunoglobulin (IM) Market Trends
 Table 135. Human Rabies Immunoglobulin (IM) Market Drivers
 Table 136. Human Rabies Immunoglobulin (IM) Market Challenges
 Table 137. Human Rabies Immunoglobulin (IM) Market Restraints
 Table 138. Research Programs/Design for This Report
 Table 139. Key Data Information from Secondary Sources
 Table 140. Key Data Information from Primary Sources
 Table 141. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Human Rabies Immunoglobulin (IM)
 Figure 2. Global Human Rabies Immunoglobulin (IM) Market Value by Type (US$ Million), 2021–2032
 Figure 3. Global Human Rabies Immunoglobulin (IM) Market Share by Type: 2025 & 2032
 Figure 4. ERIG Product Picture
 Figure 5. HRIG Product Picture
 Figure 6. Global Human Rabies Immunoglobulin (IM) Market Value by Application (US$ Million), 2021–2032
 Figure 7. Global Human Rabies Immunoglobulin (IM) Market Share by Application: 2025 & 2032
 Figure 8. Category II Exposure
 Figure 9. Category III Exposure
 Figure 10. Global Human Rabies Immunoglobulin (IM) Revenue, (US$ Million), 2021 vs 2025 vs 2032
 Figure 11. Global Human Rabies Immunoglobulin (IM) Market Size (US$ Million), 2021–2032
 Figure 12. Global Human Rabies Immunoglobulin (IM) Sales (K Units), 2021–2032
 Figure 13. Global Human Rabies Immunoglobulin (IM) Average Price (US$/Unit), 2021–2032
 Figure 14. Human Rabies Immunoglobulin (IM) Report Years Considered
 Figure 15. Human Rabies Immunoglobulin (IM) Sales Share by Manufacturers in 2025
 Figure 16. Global Human Rabies Immunoglobulin (IM) Revenue Share by Manufacturers in 2025
 Figure 17. Top 5 and Top 10 Global Human Rabies Immunoglobulin (IM) Players: Market Share by Revenue in Human Rabies Immunoglobulin (IM) in 2025
 Figure 18. Human Rabies Immunoglobulin (IM) Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
 Figure 19. Global Human Rabies Immunoglobulin (IM) Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Figure 20. North America Human Rabies Immunoglobulin (IM) Sales Market Share by Country (2021–2032)
 Figure 21. North America Human Rabies Immunoglobulin (IM) Revenue Market Share by Country (2021–2032)
 Figure 22. U.S. Human Rabies Immunoglobulin (IM) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 23. Canada Human Rabies Immunoglobulin (IM) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 24. Europe Human Rabies Immunoglobulin (IM) Sales Market Share by Country (2021–2032)
 Figure 25. Europe Human Rabies Immunoglobulin (IM) Revenue Market Share by Country (2021–2032)
 Figure 26. Germany Human Rabies Immunoglobulin (IM) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 27. France Human Rabies Immunoglobulin (IM) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 28. U.K. Human Rabies Immunoglobulin (IM) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 29. Italy Human Rabies Immunoglobulin (IM) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 30. Russia Human Rabies Immunoglobulin (IM) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 31. Asia Pacific Human Rabies Immunoglobulin (IM) Sales Market Share by Region (2021–2032)
 Figure 32. Asia Pacific Human Rabies Immunoglobulin (IM) Revenue Market Share by Region (2021–2032)
 Figure 33. China Human Rabies Immunoglobulin (IM) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 34. Japan Human Rabies Immunoglobulin (IM) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 35. South Korea Human Rabies Immunoglobulin (IM) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 36. India Human Rabies Immunoglobulin (IM) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 37. Australia Human Rabies Immunoglobulin (IM) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 38. China Taiwan Human Rabies Immunoglobulin (IM) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 39. Indonesia Human Rabies Immunoglobulin (IM) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 40. Thailand Human Rabies Immunoglobulin (IM) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 41. Malaysia Human Rabies Immunoglobulin (IM) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 42. Philippines Human Rabies Immunoglobulin (IM) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 43. Latin America Human Rabies Immunoglobulin (IM) Sales Market Share by Country (2021–2032)
 Figure 44. Latin America Human Rabies Immunoglobulin (IM) Revenue Market Share by Country (2021–2032)
 Figure 45. Mexico Human Rabies Immunoglobulin (IM) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 46. Brazil Human Rabies Immunoglobulin (IM) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 47. Argentina Human Rabies Immunoglobulin (IM) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 48. Middle East and Africa Human Rabies Immunoglobulin (IM) Sales Market Share by Country (2021–2032)
 Figure 49. Middle East and Africa Human Rabies Immunoglobulin (IM) Revenue Market Share by Country (2021–2032)
 Figure 50. Turkey Human Rabies Immunoglobulin (IM) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 51. Saudi Arabia Human Rabies Immunoglobulin (IM) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 52. U.A.E Human Rabies Immunoglobulin (IM) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 53. Global Sales Market Share of Human Rabies Immunoglobulin (IM) by Type (2021–2032)
 Figure 54. Global Revenue Market Share of Human Rabies Immunoglobulin (IM) by Type (2021–2032)
 Figure 55. Global Human Rabies Immunoglobulin (IM) Price (US$/Unit) by Type (2021–2032)
 Figure 56. Global Sales Market Share of Human Rabies Immunoglobulin (IM) by Application (2021–2032)
 Figure 57. Global Revenue Market Share of Human Rabies Immunoglobulin (IM) by Application (2021–2032)
 Figure 58. Global Human Rabies Immunoglobulin (IM) Price (US$/Unit) by Application (2021–2032)
 Figure 59. Human Rabies Immunoglobulin (IM) Value Chain
 Figure 60. Channels of Distribution (Direct Vs Distribution)
 Figure 61. Bottom-up and Top-down Approaches for This Report
 Figure 62. Data Triangulation
 Figure 63. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic

$2900

Single User License
Electronic

$4350

Multi User License
Electronic

$5800

Enterprise License
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SecuX Technology Inc

SIMILAR REPORTS

Global Human Rabies Vaccine Market Research Report 2024
Rabies Immune Globulin Human Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Human Rabies Vaccination Market Research Report 2025
Global Passive Immunizing Drugs against Rabies Market Research Report 2024
Global Rabies Antiserum Market Research Report 2024
Global Human Immunoglobulin pH4 for Intravenous Injection COVID 19 Market Research Report 2024
Global Rabies Virus Monoclonal Antibody Market Research Report 2024
Human Rho D Immune Globulin Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Human Immunoglobulin pH4 for Intravenous Injection Market Research Report 2024
Rabies Vaccine Market
Global Rabies Immunoglobulins Market Research Report 2024
Rabies Immune Globulin Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Human Rabies Immune Globulin HRIG Market Research Report 2024
Global Equine Rabies Immunoglobulin ERIG Market Research Report 2024
Rabies Immune Globulin Equine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Rabies Monoclonal Antibody Market Research Report 2024
Global Rabies Vaccination Market Research Report 2025
Global Human Immumoglobulin PH4 for Intravenous Injection Market Insights Forecast to 2030
Global Human Hyperimmune Globulins Market Research Report 2024
Global Animal Anti Rabies Vaccine Market Research Report 2024
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions